Startup Axovant Sciences Ltd. is trying to make a case for its oral Alzheimer’s drug RVT-101, finessing an answer to the tricky question of why the drug previously was dumped by GlaxoSmithKline PLC. But the field is inherently risky and the company may need more irons in the fire to keep investors happy.
Axovant is relying on the relatability of the mechanism of action for RVT-101 (SB742457, GSK742457), which is being positioned as...